3 days popular7 days popular1 month popular3 months popular

New IMI project to incorporate real life data into drug development

The Innovative Medicines Initiative (IMI) has launched a new project called GETREAL that will investigate new ways of integrating data from real life settings, such as clinics, into . This will assist healthcare decision makers when deciding how best to grant patients access to a new treatment and help pharmaceutical companies to take better decisions during .

Once a new drug has been developed, it must be reviewed by both the marketing authorisation and health technology assessment () bodies. For marketing authorisation, regulators draw on data, mostly from clinical trials, to determine if a drug is safe and works well enough to be authorised for use in patients. For their part, organisations assess the drug’s ‘relative effectiveness’, which is the extent to which a treatment does more good than harm when compared to one or more alternative treatments when provided under normal healthcare circumstances.

Ideally, HTA organisations need data from real life settings, yet there is little guidance on how to generate real world data and integrate this into drug development before launch. This is a serious issue in drug development – even if a drug is approved as safe and efficacious by the regulators, insufficient evidence supporting relative effectiveness at the time of launch may delay, or restrict, patient access to new treatments. The challenge, therefore, is to incorporate innovative study designs into the earlier stages of drug research and development, to ensure both regulators and HTA bodies get the data they need. This is where the GETREAL project comes in.

The project brings together for the first time all key stakeholders (industry, academia, regulatory agencies, health technology assessment bodies, healthcare budget holders, and patient groups) to share their perspectives and insights on how effectiveness/relative effectiveness can best be assessed in HTA decision-making processes, and so will pave the way for advancing the development of new approaches for incorporating real life data into drug development.

IMI Executive Director Michel Goldman said: ‘Collaboration between these diverse groups can be sensitive. By bringing them together in the safe harbour offered by IMI, GETREAL is in a unique position to reach a greater consensus on these issues to improve the efficiency of R&D and the decision-making processes.’

Working together, these diverse partners will analyse existing processes and methodologies for HTA. GETREAL will also generate a decision-making framework to help pharmaceutical companies design drug development strategies. A significant part of the project is devoted to organising training activities for researchers, healthcare decision makers and other stakeholders on relative effectiveness concepts and how they can be applied.

Source

Innovative Medicines Initiative (IMI)